Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG131 in Chronic Hepatitis B
NCT06263959Phase 2Recruiting
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GST-HG131 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Change from Baseline in HBsAg levels at 16 weeks. Started Dec 2023; status: recruiting.
02
Drugs
GST-HG131
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06263959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263959.